Relay Therapeutics Inc (NASDAQ: RLAY) on Monday, plunged -4.13% from the previous trading day, before settling in for the closing price of $4.36. Within the past 52 weeks, RLAY’s price has moved between $4.11 and $12.14.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 319.82%. The company achieved an average annual earnings per share of 9.80%. With a float of $123.36 million, this company’s outstanding shares have now reached $166.89 million.
Let’s determine the extent of company efficiency that accounts for 323 employees. In terms of profitability, gross margin is 58.64%, operating margin of -3926.55%, and the pretax margin is -3449.92%.
Relay Therapeutics Inc (RLAY) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Relay Therapeutics Inc is 26.30%, while institutional ownership is 73.16%. The most recent insider transaction that took place on Dec 27 ’24, was worth 20,189. Before that another transaction happened on Dec 16 ’24, when Company’s President and CEO sold 100,000 for $5.00, making the entire transaction worth $500,000. This insider now owns 574,548 shares in total.
Relay Therapeutics Inc (RLAY) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.61 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 9.80% per share during the next fiscal year.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Relay Therapeutics Inc (RLAY) is currently performing well based on its current performance indicators. A quick ratio of 18.42 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 69.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.61, a number that is poised to hit -0.57 in the next quarter and is forecasted to reach -2.64 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
Looking closely at Relay Therapeutics Inc (NASDAQ: RLAY), its last 5-days average volume was 1.45 million, which is a drop from its year-to-date volume of 1.57 million. As of the previous 9 days, the stock’s Stochastic %D was 24.69%. Additionally, its Average True Range was 0.30.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 1.06%, which indicates a significant decrease from 6.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.33% in the past 14 days, which was lower than the 92.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.18, while its 200-day Moving Average is $6.66. However, in the short run, Relay Therapeutics Inc’s stock first resistance to watch stands at $4.27. Second resistance stands at $4.35. The third major resistance level sits at $4.41. If the price goes on to break the first support level at $4.13, it is likely to go to the next support level at $4.07. Should the price break the second support level, the third support level stands at $3.99.
Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats
Market capitalization of the company is 699.66 million based on 167,383K outstanding shares. Right now, sales total 25,550 K and income totals -341,970 K. The company made 0 K in profit during its latest quarter, and -92,210 K in sales during its previous quarter.
